As the world prepares to mark International Women’s Day, a new report from the World Economic Forum reveals a striking paradox: while women represent nearly half of the global population, only 6% of private healthcare investment is directed toward their health needs. This gap is not simply a reflection of historical underfunding, it represents one of the most significant untapped opportunities in global healthcare. [bcg.com]
The Women’s Health Investment Outlook 2026, developed in collaboration with the Boston Consulting Group, offers the most comprehensive mapping to date of investment flows, unmet needs, and market potential across women’s health.
🔗Full report: https://reports.weforum.org/docs/WEF_Womens_Health_Investment_Outlook_2026.pdf
A Persistent Gap With High Economic Stakes
Despite growing awareness, investment remains heavily concentrated in only three areas: reproductive health, maternal care, and women’s cancers. More than 90% of available funds flow into these categories, leaving a wide range of high-prevalence conditions—such as cardiovascular disease, osteoporosis, menopause, and Alzheimer’s—significantly underfunded. [mckinsey.com]
Women also face a disproportionate health burden. They live longer than men, yet spend 25% more time in poor health, often due to delayed diagnoses, data gaps, and clinical standards historically oriented toward the male body. [mckinsey.com]
Addressing even four key areas – ardiovascular disease, osteoporosis, menopause, and Alzheimer’s – could unlock more than $100 billion in market opportunity by 2030. [bcg.com]
A Quote That Frames the Challenge
The report’s foreword highlights the structural nature of the problem with unmistakable clarity:
“The result is not only a public‑health shortfall but a market inefficiency on a historic scale.”
This statement captures the central truth of the Outlook: the consistent underinvestment in women’s health is simultaneously an economic blind spot and a barrier to healthier societies.
The Women’s Health Investment Index: Making the Invisible Visible
A cornerstone of the 2026 report is the Women’s Health Investment Index, which analyzes five years of private-sector investment. The Index exposes both the narrowness of current investment flows and the breadth of untapped "white space" across therapeutic areas, digital health, diagnostics, and care delivery models.
Stakeholders interviewed – including investors, global health leaders, and philanthropies – point to persistent research biases, limited sex‑specific data, and structural funding gaps as major obstacles to innovation.
A Growth Frontier Gaining Momentum
As emphasized in the report, targeted investment in women’s health strengthens productivity, resilience, and long‑term economic growth. Improving women’s health outcomes correlates with:
- Higher workforce participation
- Increased productivity
- Greater economic stability
- Reduced systemic health risks
This is not a niche investment thesis, it is a mainstream growth frontier.
Signals of Progress and What Must Come Next
At the World Economic Forum 2026 in Davos, experts highlighted accessibility, affordability, and personalization as crucial factors in closing the women’s health gap. They pointed to innovations such as AI‑powered diagnostics, improved clinical trial representation, and expanded access to preventive care as immediate levers for progress.
However, the path forward requires more than innovation. It demands:
- Better sex‑ and gender‑specific data
- Greater representation of women in research
- Sustainable financing models
- Policy frameworks that improve access and support long-term delivery system
Looking Ahead
The Women’s Health Investment Outlook 2026 makes its case unequivocally: advancing women’s health is both an ethical and economic imperative. As International Women’s Day approaches, the findings offer a timely reminder that improving women’s health is not only about equity, it is about shaping healthier societies and more resilient economies.
The data is clear, the opportunity is significant, and the moment for action is now.
This article was authored by Francine Brogyányi, Managing Partner at DORDA and Head of the Dedicated Industry Group Health & Life Science. She advises companies across pharma, biotech, medtech and digital health on regulatory, compliance and strategic matters throughout the full product lifecycle, bringing deep expertise and practical insight to a sector that could play a crucial role in closing the gender health gap.